Epigenetic regulation of HERVs: Implications for cancer immunotherapy.

Autor: Yi JM; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan, 47392, South Korea. jmyi76@inje.ac.kr.; Department of Medical & Molecular Genetics, Indiana University School of Medicine, Bloomington, IN, 47405, USA. jmyi76@inje.ac.kr.
Jazyk: angličtina
Zdroj: Genes & genomics [Genes Genomics] 2024 Nov; Vol. 46 (11), pp. 1303-1312. Date of Electronic Publication: 2024 Aug 01.
DOI: 10.1007/s13258-024-01546-2
Abstrakt: Background: Human endogenous retroviruses (HERVs), integrated into the human genome during primate evolution, constitute approximately 8% of the human genome. Although most HERVs are non-protein-coding owing to mutations, insertions, deletions, and truncations, recent research has revealed their diverse roles in biological processes, including disease pathogenesis.
Objective: Although many HERVs remain inactive, they have been implicated in various diseases, particularly cancer, prompting an increased interest in harnessing HERVs for therapeutic purposes. This review explores the recent advancements in our understanding of the biological roles of HERVs, emphasizing their clinical relevance in cancer treatment.
Methods: Here, we discuss how the detection of transposable elements (TEs), including HERVs, by the immune system triggers innate immune responses in human cancers.
Conclusion: Additionally, we outline recent progress in elucidating the implications of HERV activation in cancer and how targeting HERVs holds promise for anti-cancer treatments by modulating epigenetic plasticity and disrupting cancer initiation and progression.
Competing Interests: Declarations. Ethical approval: Not applicable. Informed consent: Not applicable. Conflict of interest: The authors declare that they have no conflict of interest.
(© 2024. The Author(s) under exclusive licence to The Genetics Society of Korea.)
Databáze: MEDLINE
Externí odkaz: